Novozymes announces the appointment of Ms. Prisca Havranek-Kosicek as new Chief Financial Officer effective February 1, 2018.
Ms. Havranek-Kosicek has up until November 2017 served as CFO and member of the Executive Board for Kuoni Group, a leading 8,000-employee service provider to the global travel industry. In the period 2011-2016 Ms. Havranek-Kosicek held positions at Royal DSM, including Group Treasurer and CFO for DSM’s pharmaceutical division, and from 2004-2008 she served as VP Corporate Subsidiaries and Investor Relations for Austrian Airlines Group.
CEO Peder Holk Nielsen says: “With a strong business acumen from international positions around the world, a thorough understanding of the different finance functions and knowledge of Novozymes’ markets, Prisca brings the right competencies and drive to support our future growth. I’m very pleased to see her become part of our Executive Leadership Team.”
Ms. Prisca Havranek-Kosicek says: “I’m honored to join Novozymes, the global leader in biological solutions with a strong cultural heritage and values. What sets Novozymes apart is the company’s innovation track record and its commitment to help solve some of the pressing global challenges facing the world today. I look forward to working with the great people at Novozymes to continue this journey.”
Ms. Havranek-Kosicek (1975) is an Austrian citizen. She currently lives in Zurich, Switzerland, and will relocate to Denmark during 2018 with her family. She has previously worked in Austria, Germany, the Netherlands, Malaysia and the US.
Ms. Havranek-Kosicek holds a Ph.D. in Business Administration from the Vienna University of Economics and Business. She serves as member of the Supervisory Board of Allianz Elementar Versicherungs-AG and Allianz Elementar Lebensversicherungs-AG.
Ms. Havranek-Kosicek will take part in the 2017-2019 Executive Leadership Team’s incentive program on a proportional basis from February 1, 2018. A description of this program, introduced on January 18, 2017, can be found in the “Group financial statement for 2016. Company announcement No. 1.”
Source: Novozymes
Neste Corporation’s Board of Directors has appointed Heikki Malinen, M.Sc. (Econ.), MBA (Harvard) as the President and CEO of Neste as of 2 November 2024, at the latest. Malinen joins Neste from Outokumpu Corporation where he has held the position of President and CEO since 2020.
Petrochemicals company Sasol has announced that CFO and executive director Hanré Rossouw will step down from his position, effective October 31. Sasol has started the process to appoint a successor. Rossouw will still oversee the publication of Sasol’s reports for the financial year ending June 30, to allow for a structured handover period.
Chemours announced its CFO Jonathan Lock has resigned from all positions within the company, according to an SEC 8-K filing on April 23. The resignation comes in the aftermath of the company announcing that Lock, former CEO Mark Newman, and principal accounting officer Camela Wisel, had been placed on administrative leave.
